Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 111

Sort by

Sort Order Select

Journal Articles

Hyperleukocytosis Increases the Risk of Early Relapses Independently of Genetics in AML

Raphaël Liévin, Nicolas Duployez, Loïc Vasseur, Juliette Lambert, Mael Heiblig, Mathilde Hunault, Claude Gardin, Stephane De Botton, Elise Fournier, Cecile Pautas, Christine Terré, Eric Delabesse, Norbert Ifrah, Arnaud Pigneux, Celli-Lebras Karine, Christian Recher, Claude Preudhomme, Herve Dombret, Raphael Itzykson

Blood (2023) 142 (Supplement 1): 4322.

https://doi.org/10.1182/blood-2023-173614

Published: 2023

Journal Articles

Treatment of Adverse-Risk and Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients with FLAG-IDA ± Venetoclax and CLAG-M: A Monocentric Experience

Ramy Rahmé, Valérie Vidal, Thomas Hueso, Lucie Le Meur, Marthe Rigal, Sarah Ivanoff, Sabine Brechignac, Regis Peffault De Latour, Claude Gardin, Thorsten Braun

Blood (2023) 142 (Supplement 1): 1520.

https://doi.org/10.1182/blood-2023-174356

Published: 2023

Journal Articles

Venetoclax in Combination with Intermediate Doses of Cytarabine in Consolidation Phase for Acute Myeloid Leukemia Patients in First Complete Remission; Results of the Part 1 of the Phase 1/2 Multicentric Covenidac Study

Blood (2023) 142 (Supplement 1): 4261.

https://doi.org/10.1182/blood-2023-173656

Published: 2023

Journal Articles

Current Results of Intensive Therapy in Younger Adults with Acute Myeloid Leukemia (AML): The Large Randomized French Backbone Intergroup (BIG)-1 Study on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Blood (2023) 142 (Supplement 1): 967.

https://doi.org/10.1182/blood-2023-179376

Published: 2023

Journal Articles

Prognostic Impact of Monoallelic Versus Biallelic TP53 Alterations in Intensively-Treated Adults AML Patients: A Retrospective Study from the ALFA Group

Laurène Fenwarth, Loïc Vasseur, Nicolas Duployez, Claude Gardin, Christine Terré, Juliette Lambert, Stéphane de Botton, Karine Celli-Lebras, Pascal Turlure, Thomas Cluzeau, Thorsten Braun, Xavier Thomas, Christian Recher, Sylvain Chantepie, Cécile Pautas, Hervé Dombret, Claude Preudhomme, Raphael Itzykson

Blood (2022) 140 (Supplement 1): 737–738.

https://doi.org/10.1182/blood-2022-163044

Published: 2022

Journal Articles

Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL): Results of the EWALL-INO Study

Patrice Chevallier, Thibault Leguay, Rathana KIM, Marc Delord, Michael Doubek, Francoise Huguet, Aurelie Cabannes-Hamy, Ulla Wartiovaara-Kautto, Colombe Saillard, Emmanuel Raffoux, Thomas Cluzeau, Stephane Lepretre, Marie Balsat, Anna Berceanu, Nicolas Boissel, Claude Gardin, Emmanuelle Clappier, Herve Dombret, Philippe Rousselot

Blood (2022) 140 (Supplement 1): 6114–6116.

https://doi.org/10.1182/blood-2022-166035

Published: 2022

Journal Articles

Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study

Blood (2022) 140 (7): 756–768.

https://doi.org/10.1182/blood.2021015328

Published: 2022

Includes: Supplemental data

Journal Articles

Replacing the Anthracycline By Gemtuzumab Ozogamicin in Older Patients with De Novo Standard-Risk Acute Myeloid Leukemia Treated Intensively - Results of the Randomized ALFA1401-Mylofrance 4 Study

Blood (2021) 138 (Supplement 1): 31.

https://doi.org/10.1182/blood-2021-145152

Published: 2021

Journal Articles

Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy Provides Very Good Outcome in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: First Results from the EWALL-INO Study

Patrice Chevallier, Thibault Leguay, Michael Doubek, Francoise Huguet, Cyril Salek, Aurélie Cabannes, Ulla Wartiovaara-Kautto, Colombe Saillard, Emmanuel Raffoux, Thomas Cluzeau, Stéphane Leprêtre, Marie Balsat, Anna Berceanu, Nicolas Boissel, Emmanuelle Clappier, Laure Morisset, Claude Gardin, Hervé Dombret, Philippe Rousselot

Blood (2021) 138 (Supplement 1): 511.

https://doi.org/10.1182/blood-2021-148625

Published: 2021

Journal Articles

Prognostic Significance of DDX41 Germline Mutations in Intensively Treated AML Patients: An ALFA-Filo Study

Nicolas Duployez, Matthieu Duchmann, Laetitia Largeaud, Juliette Lambert, Audrey Bidet, Emmanuelle Clappier, Xavier Thomas, Stephane de Botton, Claude Gardin, Christian Recher, Arnaud Pigneux, Raphael Itzykson, Claude Preudhomme, Hervé Dombret, Eric Delabesse, Marie Sebert

Blood (2021) 138 (Supplement 1): 612.

https://doi.org/10.1182/blood-2021-148465

Published: 2021

Journal Articles

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

Blood (2021) 138 (7): 507–519.

https://doi.org/10.1182/blood.2021011103

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostic significance of concurrent gene mutations in intensively treated patients with IDH -mutated AML: an ALFA study

Blood (2021) 137 (20): 2827–2837.

https://doi.org/10.1182/blood.2020010165

Published: 2021

Includes: Supplemental data

Journal Articles

A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia

Blood (2021) 137 (4): 524–532.

https://doi.org/10.1182/blood.2020005524

Published: 2021

Includes: Supplemental data

Journal Articles

Comparison of a Combination of Vosaroxin (VOS) and Intermediate-Dose Cytarabine (IDAC) with Idac for the Consolidation Therapy of Younger Patients with Favorable- and Intermediate-Risk Acute Myeloid Leukemia (AML) in First Complete Remission (CR): Preliminary Results of a Randomized Phase 2 R4-VOS Study of the French ALFA-Filo AML Intergroup

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-137032

Published: 2020

Journal Articles

Very Long Term Follow up a Phase II Study of Post-Remission Subcutaneous (SC) Azacitidine (AZA) in Patients with AML Post-MDS or Higher-Risk (HR) MDS

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-137012

Published: 2020

Journal Articles

Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL)

Anna Kaci, PhD, Emilie Adiceam, Melanie Dupont, Marine Garrido, Jeannig Berrou, Hanane Djamai, Andre Baruchel, Mike Burbridge, Claude Gardin, Herve Dombret, MD PhD, Thorsten Braun, MD

Blood (2019) 134 (Supplement_1): 2631.

https://doi.org/10.1182/blood-2019-125641

Published: 2019

Journal Articles

Prognostic Significance of Concurrent Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML

Blood (2019) 134 (Supplement_1): 1416.

https://doi.org/10.1182/blood-2019-127082

Published: 2019

Journal Articles

A Single Center Experience of Cladribine, Cytarabine, Filgrastim and Mitoxantrone (CLAG-M regimen) in High-Risk or Relapsed/Refractory, Acute Myeloid Leukemia (AML)

Valérie Vidal, Laila Hamri, Alice Marceau-Renaut, Flore Sicre De Fontbrune, MD PhD, Virginie Eclache, Nevine Osman, Benjamin Papoular, Daniel Lusina, Sabine Brechignac, Regis Peffault De Latour, Claude Preudhomme, Claude Gardin, Thorsten Braun, MD PhD

Blood (2018) 132 (Supplement 1): 4007.

https://doi.org/10.1182/blood-2018-99-117237

Published: 2018

Journal Articles

Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial

Blood (2018) 132 (Supplement 1): 993.

https://doi.org/10.1182/blood-2018-99-111144

Published: 2018

Journal Articles

Combination of BCR-ABL1 Tyrosine Kinase Inhibitors with a Small Molecule LIM kinase1/2 Inhibitor in BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL)

Thorsten Braun, MD PhD, Jeannig Berrou, Renaud Prudent, Hanane Djamai, Melanie Dupont, Anna Kaci, Emilie Adiceam, Fabrice Paublant, Andre Baruchel, MD, Jacques Ghysdael, Claude Gardin, Herve Dombret

Blood (2018) 132 (Supplement 1): 2705.

https://doi.org/10.1182/blood-2018-99-115933

Published: 2018

NARROW

Hyperleukocytosis Increases the Risk of Early Relapses Independently of Genetics in AML

Treatment of Adverse-Risk and Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients with FLAG-IDA ± Venetoclax and CLAG-M: A Monocentric Experience

Venetoclax in Combination with Intermediate Doses of Cytarabine in Consolidation Phase for Acute Myeloid Leukemia Patients in First Complete Remission; Results of the Part 1 of the Phase 1/2 Multicentric Covenidac Study

Current Results of Intensive Therapy in Younger Adults with Acute Myeloid Leukemia (AML): The Large Randomized French Backbone Intergroup (BIG)-1 Study on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Prognostic Impact of Monoallelic Versus Biallelic TP53 Alterations in Intensively-Treated Adults AML Patients: A Retrospective Study from the ALFA Group

Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL): Results of the EWALL-INO Study

Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study

Replacing the Anthracycline By Gemtuzumab Ozogamicin in Older Patients with De Novo Standard-Risk Acute Myeloid Leukemia Treated Intensively - Results of the Randomized ALFA1401-Mylofrance 4 Study

Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy Provides Very Good Outcome in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: First Results from the EWALL-INO Study

Prognostic Significance of DDX41 Germline Mutations in Intensively Treated AML Patients: An ALFA-Filo Study

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

Prognostic significance of concurrent gene mutations in intensively treated patients with IDH -mutated AML: an ALFA study

A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia

Very Long Term Follow up a Phase II Study of Post-Remission Subcutaneous (SC) Azacitidine (AZA) in Patients with AML Post-MDS or Higher-Risk (HR) MDS

Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL)

Prognostic Significance of Concurrent Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML

A Single Center Experience of Cladribine, Cytarabine, Filgrastim and Mitoxantrone (CLAG-M regimen) in High-Risk or Relapsed/Refractory, Acute Myeloid Leukemia (AML)

Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial

Combination of BCR-ABL1 Tyrosine Kinase Inhibitors with a Small Molecule LIM kinase1/2 Inhibitor in BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only